Sinclair Pharma Selects QAD DynaSys Cloud Solutions to Support Integrated Business Planning and Improve Customer Service

Rhea-AI Summary

QAD DynaSys announces its partnership with Sinclair Pharma, a subsidiary of Huadong Medicine, to implement its Digital Supply Chain Planning (DSCP) solution. This solution aims to enhance forecast accuracy and customer service levels while improving profitability through better inventory management. Sinclair Pharma cited the need for a more scalable system due to its rapid growth. Key benefits include reduced administrative costs, enhanced decision-making capabilities, and improved long-term business planning.

Positive

• Partnership with Sinclair Pharma enhances brand visibility and demand for QAD DynaSys' solutions.
• Expected improvement in forecast accuracy and customer service levels for Sinclair Pharma.
• Reduction in inventory levels anticipated to improve profitability and cash flow.
• Enhanced long-term business planning capabilities for Sinclair Pharma.
• Increased efficiency through lowered administrative costs associated with supply chain planning.

Negative

• None.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- QAD DynaSys, a leading provider of digital supply chain planning solutions, announced today that Sinclair Pharma, a pure play aesthetics company and fully-owned subsidiary of Huadong Medicine Company Limited, has selected the QAD DynaSys DSCP (Digital Supply Chain Planning) solution including demand planning, and distribution planning capabilities to support IBP (Integrated Business Planning) and improve forecast accuracy and customer service level. QAD DynaSys is a division of QAD Inc. (Nasdaq: QADA) (Nasdaq: QADB).

“Sinclair Pharma is growing fast, and the current systems infrastructure is not scalable enough for our needs,” said Roy Morris, head of manufacturing and supply at Sinclair Pharma. “Our objective is to improve forecast accuracy and collaboration among customers, commercial management and the central supply chain function as well as control and manage inventory through an integrated distribution requirement planning process.”

Demand and Distribution Planning to Support Integrated Business Planning (IBP)

Sinclair Pharma management identified the need to develop and improve their forecasting and distribution requirements planning process.

The QAD DynaSys solution will enable Sinclair Pharma to:

• Improve customer service levels by having the right product at the right place and on time by utilizing the planning capabilities of DSCP, which will also allow for reduced inventory levels, thus enabling improved profitability and cash flow.
• Improve long-term business planning capabilities, thereby helping to make sure the business invests in the right assets at the right time.
• Improve the decision-making capability of the organization – mainly through the ability to review different scenarios quickly and effectively.
• Reduce the administrative costs currently associated with its supply chain planning process.
• Enable the business to aggregate and review revenues and gross margins to enable continual review of current commercial volumes, values and profitability.

“The QAD DynaSys team has demonstrated the capabilities of its digital supply chain planning solution to cover everything from demand to distribution and rough-cut capacity planning,” added Morris. “It showcased how we could utilize the advanced collaboration and financial reporting functionality of the solution to support our Integrated Business Planning process.”

Sinclair Pharma selected QAD DynaSys for a number of reasons including:

• QAD DynaSys’ robust, integrated, flexible and collaborative end-to-end digital supply chain planning solution
• The ability to support IBP and decision making
• The solution's easy-to-use and rapid deployment
• The deep domain expertise of the QAD DynaSys team in the pharmaceutical and medical device business areas and QAD DynaSys’ ability to support Sinclair Pharma’s growth in the future

“We are proud that Sinclair Pharma has chosen QAD DynaSys to support their growth and supply chain future challenges,” said QAD DynaSys President Ariel Weil. “It is clear that QAD DynaSys is the ideal partner to help pharmaceutical companies to structure their supply chain to gain competitiveness, agility and visibility throughout their end-to-end supply chain.”

About QAD DynaSys – Digital Supply Chain Planning Solutions

QAD DynaSys, a division of QAD Inc. (Nasdaq: QADA) (Nasdaq: QADB), provides Digital Supply Chain Planning solutions. With 35 years of experience, QAD DynaSys provides an integrated and collaborative planning solution that allows businesses to optimize their supply chains, including sales and operations planning, demand planning, network and inventory and business resources optimizations. QAD DynaSys software enables customers and partners in the food and beverage, consumer packaged goods, life sciences, apparel, luxury, high tech, automotive, distribution and retail verticals to meet their goals of better managing Demand and Supply Chain Planning, and building the future of their supply chain.

For more information about QAD DynaSys, visit www.dys.com or email contact@dys.com.

About Sinclair Pharma

Sinclair Pharma, a subsidiary of Huadong Medicine Limited, is an international company, operating in the expanding global aesthetics market. Sinclair is experiencing significant growth having built a strong and differentiated portfolio of complementary aesthetics technologies, focused on two key market segments; injectables and energy-based devices. It targets unmet clinical needs for effective, high quality, longer duration, natural looking and minimally invasive treatments.

Sinclair directly employs over 500 people, operating from corporate headquarters in London with administration conducted from offices in Chester, UK. Energy-based devices are headquartered in Barcelona, with central marketing in Paris and sales offices in Shanghai, Sao Paolo, Mexico City, Bogota, Seoul, London, Paris, Madrid, Barcelona, Milan, Warsaw, Heidelberg, Dubai and Moscow.

For more information, visit www.sinclairpharma.com

Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding projections of revenue, income and loss, capital expenditures, plans and objectives of management regarding the company's business, future economic performance or any of the assumptions underlying or relating to any of the foregoing. Forward-looking statements are based on the company's current expectations. Words such as "expects," "believes," "anticipates," "could," "will likely result," "estimates," "intends," "may," "projects," "should," "would," "might," "plan" and variations of these words and similar expressions are intended to identify these forward-looking statements. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to: risks associated with our cloud service offerings, such as defects and disruptions in our services, our ability to properly manage our cloud service offerings, our reliance on third-party hosting and other service providers, and our exposure to liability and loss from security breaches; demand for the company's products, including cloud service, licenses, services and maintenance; pressure to make concessions on our pricing and changes in our pricing models; protection of our intellectual property; dependence on third-party suppliers and other third-party relationships, such as sales, services and marketing channels; changes in our revenue, earnings, operating expenses and margins; the reliability of our financial forecasts and estimates of the costs and benefits of transactions; the ability to leverage changes in technology; defects in our software products and services; third-party opinions about the company; competition in our industry; the ability to recruit and retain key personnel; delays in sales; timely and effective integration of newly acquired businesses; economic conditions in our vertical markets and worldwide; exchange rate fluctuations; and the global political environment. For a more detailed description of the risk factors associated with the company and factors that may affect our forward-looking statements, please refer to the company's latest Annual Report on Form 10-K and, in particular, the section entitled "Risk Factors" therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter. Management does not undertake to update these forward-looking statements except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005143/en/

QAD DynaSys

Arnaud Hédoux

Marketing Director

+33 (0)3 88 19 14 14

contact@dys.com

or

QAD Inc.

Scott Matulis

Public Relations

818-451-8918

publicrelations@qad.com

or

Evan Quinn

Analyst Relations

617-869-7335

industryanalyst@qad.com

Source: QAD DynaSys

FAQ

What is the partnership between QAD DynaSys and Sinclair Pharma?

QAD DynaSys is providing its Digital Supply Chain Planning solution to Sinclair Pharma to improve forecasting and customer service levels.

How will the QAD DynaSys solution benefit Sinclair Pharma?

It will enhance forecast accuracy, reduce inventory levels, and improve decision-making capabilities.

What are the stock symbols for QAD DynaSys?

The stock symbols are QADA and QADB.

When was the partnership between QAD DynaSys and Sinclair Pharma announced?

The partnership was announced on September 7, 2021.

What is the main goal of implementing the QAD DynaSys solution?

The main goal is to improve forecast accuracy and optimize supply chain operations for Sinclair Pharma.